Bazetta Blacklock-Schuver

Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease

Jennifer N. Brudno, Robert Somerville, Victoria Shi et al. · Journal of Clinical Oncology · 2016 · 609 citations · Full text

Life Sciences, Hematology, Immunology +13

Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation

James N. Kochenderfer, Mark E. Dudley, Robert O. Carpenter et al. · Blood · 2013 · 590 citations · Full text

Medicine, Hematology, Immunology +13

Costimulated tumor-infiltrating lymphocytes are a feasible and safe alternative donor cell therapy for relapse after allogeneic stem cell transplantation

Nancy M. Hardy, Vicki Fellowes, Jeremy J. Rose et al. · Blood · 2012 · 18 citations · Full text

Medicine, Immunology, Oncology +16

Outcomes of Related and Unrelated Donor Searches Among Patients with Primary Immunodeficiency Diseases Referred for Allogeneic Hematopoietic Cell Transplantation

Mary Joseph Acevedo, Jennifer Wilder, Sharon Adams et al. · Biology of Blood and Marrow Transplantation · 2019 · 16 citations · Full text

Medicine, Hematology, Immunology +17

Dramatic Regression of Chronic Lymphocytic Leukemia in the First Patient Treated With Donor-Derived Genetically-Engineered Anti-CD19-Chimeric-Antigen-Receptor-Expressing T Cells After Allogeneic Hematopoietic Stem Cell Transplantation

James N. Kochenderfer, Mark E. Dudley, I. Maric et al. · Biology of Blood and Marrow Transplantation · 2011 · 10 citations · Full text

Life Sciences, Hematology, Immunology +17